Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial
Key facts
- Who runs it
- Piotr Czempik
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- 10 Nov 2024
- Expected to end
- 1 Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Iron
- EPO
- 0.9 % NaCl
- Record updated
- 27 December 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- age ≥18,
- diagnosed sepsis (Sepsis-3) or septic shock (Septic Shock-3),
- hemoglobin <120 g/L in both sexes
Who cannot take part
- bleeding,
- decompensated liver disease,
- inherited microcytic disorders,
- allergy to epoetin alfa and/or iron derisomaltose,
- macrocytosis,
- contraindications to pharmacological prophylaxis of VTE,
- pregnancy,
- ferritin concentration >800 ng/mL,
- unable to take informed consent
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Anemia or sepsis or septic shock
This trial is currently available in Poland.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background Up to 66% of have anemia at the admission to the intensive care unit. This number increases to 95% after 72 hours of hospitalization in the intensive care unit due to illness and iatrogenic blood loss. Anemia worsens tissue oxygenation, especially in patietns with sepsis or septic shock, who already have blood flow issues. Instead of giving blood transfusions, which can have side effects, we aim to address the root causes of anemia in these patients. Sepsis can cause "inflammatory anemia" and combine with iron deficiency anemia. Current anemia treatments include drugs that stimulate red blood cell production and intravenous iron supplements. Some think that iron supplements can worsen infections by feeding pathogens, but this is not conclusively proven. Since transfused red blood cells (RBC) also contain iron, small doses of intravenous iron might help sepsis patients with iron deficiency.
Read full original descriptionShow less
There is a need for a study on the effects of epoetin alfa and iron derisomaltose on hemoglobin (Hb) levels in sepsis patients.
Hypothesis and Aim Treating anemia in sepsis patients could increase Hb levels and reduce RBC transfusions, improving patient outcomes. This study aims to evaluate the effects of epoetin alfa ± iron derisomaltose on Hb levels and RBC transfusion rates.
Primary Endpoints:
1. Hb difference at study exit (discharge from ICU/death/bleeding/need for surgery/day 15 whatever comes first) and day 1 corrected for Hb increase due to possible RBC transfusion
Secondary Endpoints:
1. Hb difference on days 8 and 1 corrected for Hb increase due to possible RBC transfusion 2. Hb difference on days 15 and 1 corrected for Hb increase due to possible RBC transfusion 3. number of blood transfusions 4. percentage of patients receiving at least one blood transfusion 5. actual vs. predicted mortality 6. prevalence of deep vein thrombosis and pulmonary embolism 7. mortality rates in ICU, hospital, 30-day, and 90-day.
Materials and Methods:
This will be a randomized controlled clinical trial recruting 200 patients
Inclusion Criteria:
1. age ≥18 2. diagnosed sepsis (Sepsis-3 definition) or septic shock (Septic Shock-3 definition) 3. hemoglobin <120 g/L for both sexes
Exclusion Criteria:
1. bleeding 2. decompensated liver disease 3. inherited microcytic disorders 4. macrocytosis 5. contraindications to pharmacological prophylaxis for venous thromboembolism 6. pregnancy 7. allergy to epoetin alfa and/or iron derisomaltose. 8. ferritin >800 ng/mL. 9. inability to take consent
Study Group:
1. epoetin alfa 50 u/kg IV (days 1, 3, 5, 8, 10, 12) 2. iron derisomaltose 0.2g IV when RET-He <29.3 pg (days 1, 3, 5, 8, 10, 12) 3. algorithm for red blood cell transfusions
Control Group:
1. algorithm for red blood cell transfusions
Laboratory Parameters:
Initial: interleukin-6, procalcitonin, C-reactive protein, creatinine, ammonia, blood urea nitrogen, aspartate aminotransferase, alanine aminotransferase, total bilirubin, complete blood count (CBC), reticulocytes (RET), ferritin, iron, transferrin.
Serial: CBC and RET (days 1, 3, 5, 8, 10, 12)
The 2 groups in the trial
- Epoetin alfa +/- ferric derisomaltoseTreatment being tested
Epoetin alfa 50 units/kg IV 3 times weekly and ferric derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg
Treatment: Iron and EPO
- PlaceboPlacebo, for comparison
0.9% NaCl
Treatment: 0.9 % NaCl
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Use of Epoetin Alfa and Iron Derisomaltose in the Treatment of Anemia in Patients With Sepsis or Septic Shock Hospitalized in the Intensive Care Unit: a Randomized Controlled Clinical Trial
- Criteria questions
- Built from NCT06670963, who can take part
- Record updated
- 27 December 2024